Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael E. Herrtage is active.

Publication


Featured researches published by Michael E. Herrtage.


Nature Communications | 2015

Capturing the cloud of diversity reveals complexity and heterogeneity of MRSA carriage, infection and transmission

Gavin K. Paterson; Ewan M. Harrison; Gemma Gr Murray; John J. Welch; James H Warland; Matthew T. G. Holden; Fiona J. E. Morgan; Xiaoliang Ba; G. Koop; Simon R. Harris; Duncan J. Maskell; Sharon J. Peacock; Michael E. Herrtage; Julian Parkhill; Mark A. Holmes

Genome sequencing is revolutionizing clinical microbiology and our understanding of infectious diseases. Previous studies have largely relied on the sequencing of a single isolate from each individual. However, it is not clear what degree of bacterial diversity exists within, and is transmitted between individuals. Understanding this ‘cloud of diversity’ is key to accurate identification of transmission pathways. Here, we report the deep sequencing of methicillin-resistant Staphylococcus aureus among staff and animal patients involved in a transmission network at a veterinary hospital. We demonstrate considerable within-host diversity and that within-host diversity may rise and fall over time. Isolates from invasive disease contained multiple mutations in the same genes, including inactivation of a global regulator of virulence and changes in phage copy number. This study highlights the need for sequencing of multiple isolates from individuals to gain an accurate picture of transmission networks and to further understand the basis of pathogenesis.


Journal of Veterinary Internal Medicine | 2005

A Comparison of the Survival Times of Dogs Treated with Mitotane or Trilostane for Pituitary-Dependent Hyperadrenocorticism

E.N. Barker; S. Campbell; A.J. Tebb; Reto Neiger; Michael E. Herrtage; S. Reid; Ian Ramsey

The survival times of 148 dogs treated for pituitary-dependent hyperadrenocorticism were studied using clinical records from 3 UK veterinary centers between 1998 and 2003. Of these animals, 123 (83.1%) were treated with trilostane, while 25 (16.9%) were treated with mitotane. Treatment groups were compared using t-tests and analysis of variance (or their nonparametric equivalents) and chi-square tests. Survival data were analyzed using Kaplan-Meier survival plots and Cox proportional hazard methods. There was no significant difference between the population attributes from each center or between treatment groups. The median survival time for animals treated with trilostane was 662 days (range 8-1,971) and for mitotane it was 708 days (range 33-1,399). There were no significant differences between the survival times for animals treated with trilostane and those treated with mitotane. In the multivariable model (including drug, center, breed group, weight, diagnostic group, and age at diagnosis), only age at diagnosis and weight were significantly negatively associated with survival. Importantly, there was no significant effect of drug choice on survival.


Veterinary Immunology and Immunopathology | 2008

Autoantibodies to GAD65 and IA-2 in canine diabetes mellitus.

L. J. Davison; Sarah M. Weenink; Michael R. Christie; Michael E. Herrtage; Brian Catchpole

Diabetes mellitus in dogs shares many characteristics with the human type 1 disease and virtually all diabetic dogs require insulin therapy to control hyperglycaemia. Insulin deficiency is suspected to result from immune-mediated destruction of pancreatic beta cells in some cases. Human patients suffering from Type 1A (immune-mediated) diabetes or latent autoimmune diabetes of the adult (LADA) demonstrate circulating autoantibodies against the 65kDa isoform of glutamic acid decarboxylase (GAD65) and/or insulinoma antigen-2 (IA-2). The aims of the current study were to develop radio-immunoassays to detect serum antibodies against recombinant canine GAD65 and IA-2 and to identify diabetic dogs showing serological evidence of autoreactivity to these pancreatic beta cell antigens. Canine GAD65 and the 3 end of IA-2 (coding for amino acids 771-979 of the intracellular domain) were amplified by PCR from cDNA prepared from canine insulinoma tissue and cloned into the pCRII vector. The canine sequences were later confirmed by identifying GAD2 and PTPRN genes from the dog genome assembly. Recombinant (35)S-methionine-radiolabelled canine GAD65 and IA-2 (771-979) proteins were used in radio-immunoprecipitation assays to screen sera from 30 newly diagnosed diabetic dogs and 30 control dogs. Four of 30 canine diabetic patients had significant GAD65 autoreactivity (p<0.01) compared to controls and 3 dogs were positive for autoantibodies to IA-2 (771-979). Two diabetic dogs showed dual autoantigen reactivity. These preliminary data indicate that serological reactivity to GAD65 and IA-2 is present in a proportion of diabetic dogs and suggests that, in some cases, canine diabetes is associated with an autoimmune response to these antigens.


Journal of Feline Medicine and Surgery | 2005

Evaluation of a continuous glucose monitoring system in cats with diabetes mellitus.

Jelena Ristic; Michael E. Herrtage; Sabine M.M. Walti-Lauger; Linda Slater; David B. Church; L. J. Davison; Brian Catchpole

A continuous glucose monitoring system (CGMS) was evaluated in 14 cats with naturally occurring diabetes mellitus. The device measures interstitial fluid glucose continuously, by means of a sensor placed in the subcutaneous tissue. All cats tolerated the device well and a trace was obtained on 15/16 occasions. There was good correlation between the CGMS values and blood glucose concentration measured using a glucometer (r=0.932, P<0.01). Limitations to the use of the CGMS are its working glucose range of 2.2–22.2 mmol/l (40–400 mg/dl) and the need for calibration with a blood glucose measurement at least every 12 h. When compared to a traditional blood glucose curve, the CGMS is minimally invasive, reduces the number of venepunctures necessary to assess the kinetics of insulin therapy in a patient and provides a truly continuous glucose curve.


Journal of Veterinary Cardiology | 2006

High serum troponin I concentration as a marker of severe myocardial damage in a case of suspected exertional heatstroke in a dog

Paul J. Mellor; Richard Mellanby; Elizabeth A. Baines; Elizabeth J. Villiers; Joy Archer; Michael E. Herrtage

A young, overweight dog presented with sudden onset lethargy and collapse following exercise in warm environmental conditions. Investigations revealed systolic hypotension, multiform ventricular premature complexes, irregular myocardial echogenicity with poor left ventricular systolic function and a markedly elevated troponin cTnI (180ng/mL, reference range <0.3ng/mL) consistent with severe myocyte damage. Infectious causes of myocarditis were ruled out on the basis of serological and polymerase chain reaction blood tests. Exercise-induced malignant hyperthermia was excluded from the history, an exercise tolerance test and genetic testing for the RYR1 V547A mutation. The diagnosis was myocardial damage secondary to suspected exertional heatstroke, from which the dog recovered uneventfully over a number of weeks and serum troponin normalised. This is the first case report in any species including man, documenting high troponin as a marker of severe myocardial damage following suspected heatstroke.


Veterinary Immunology and Immunopathology | 2003

Anti-insulin antibodies in dogs with naturally occurring diabetes mellitus

L. J. Davison; Jelena Ristic; Michael E. Herrtage; Ian Ramsey; Brian Catchpole

The presence of anti-insulin antibodies was determined by ELISA in serum samples from 30 diabetic dogs receiving bovine insulin therapy and 30 normoglycaemic dogs. Twenty of the diabetic dogs had significant reactivity to both bovine (heterologous) and porcine (homologous) insulin compared to control dogs. In contrast there was no significant difference between the two populations in reactivity to canine distemper virus (CDV) or canine thyroglobulin. The high degree of correlation between anti-bovine insulin and anti-porcine insulin antibodies suggested cross-reactivity which was confirmed by performing a competition ELISA, with antibody binding to bovine insulin inhibited by pre-incubating serum with porcine insulin. The insulin B-chain, rather than the A-chain was the most reactive component of the insulin molecule although in some cases, diabetics with antibody reactivity to whole insulin protein showed minimal reactivity to the individual subunits. The data suggest that treatment of diabetic dogs with bovine insulin can lead to anti-insulin antibody production. These antibodies cross-react with homologous insulin and recognise conformational as well as linear epitopes.


Journal of Veterinary Internal Medicine | 2009

Exogenous insulin treatment after hypofractionated radiotherapy in cats with diabetes mellitus and acromegaly.

Mark Dunning; C.S. Lowrie; Nicholas Bexfield; Jane Dobson; Michael E. Herrtage

BACKGROUNDnThe optimal treatment for feline acromegaly has yet to be established. Surgical and medical therapies are minimally effective although radiotherapy might have greater efficacy. The purpose of this study was to review the response and outcome of cats with acromegaly and insulin-resistant diabetes mellitus (DM) to radiotherapy.nnnHYPOTHESESnThat radiotherapy improves glycemic control in cats with acromegaly and that improved glycemic control is due to remission of clinical acromegaly; demonstrated by a fall in serum insulin-like growth factor-1 (IGF-1) concentrations.nnnANIMALSnFourteen cats with naturally occurring acromegaly.nnnMETHODSnRetrospective case review; records of all cats treated for acromegaly with radiotherapy were reviewed from 1997 to 2008. Cats were selected on the basis of compatible clinical signs, laboratory features, and diagnostic imaging findings. Fourteen cats received radiotherapy, delivered in 10 fractions, 3 times a week to a total dose of 3,700 cGy.nnnRESULTSnThirteen of 14 cats had improved diabetic control after radiotherapy. These improvements were sustained for up to 60 months. DM progressed in 2 cats and 1 did not respond. Seven cats responded before the final treatment. Ten cats were euthanized, 1 as a consequence of radiotherapy. In 8 cats in which IGF-1 was measured after treatment, changes in its concentration did not reflect the clinical improvement in glycemic control.nnnCONCLUSIONS AND CLINICAL IMPORTANCEnRadiotherapy represents an effective treatment for cats with insulin-resistant DM resulting from acromegaly. IGF-1 concentration after treatment does not provide a suitable method by which remission from either acromegaly or insulin-resistant DM may be assessed.


Journal of Veterinary Cardiology | 2001

Congenital Pulmonic Stenosis a Retrospective study of 24 cases seen between 1990–1999

Jelena Ristic; Carmen J. Marin; Elizabeth A. Baines; Michael E. Herrtage

BACKGROUNDnPBV is the treatment of choice for humans with pulmonic stenosis and whilst this procedure has been used in dogs the longer term benefits remain to be evaluated.nnnOBJECTIVESnThe purpose of this study was to evaluate the long term effects of pulmonary balloon valvuloplasty (PBV) in dogs with congenital pulmonic stenosis, with respect to clinical signs, echocardiographic parameters and survival time. Methods - Pulmonic stenosis was diagnosed in 24 dogs between 1990-1999. Eighteen cases were treated with PBV, six were not treated.nnnRESULTSnTwelve of the treated cases were alive and asymptomatic at the time of writing. Follow up periods ranged from six months to nine years post PBV. Prior to treatment the mean Doppler pressure gradient across the pulmonic valve was 98mmHg, 24 hours post treatment the mean was 65mmHg and in the long term this was maintained at 64mmHg. Three of the dogs (17 per cent) treated with PBV restenosed during the follow up period. Four of the six untreated dogs were alive at the time of writing, two to four and a half years after presentation. The mean Doppler gradient for this group was 89 mm Hg on presentation.nnnCONCLUSIONnAt this stage in the follow up period there is no significant difference in survival times between the treated and untreated groups. However, symptomatic dogs with pulmonic stenosis treated with PBV have experienced a reduction in clinical signs and therefore an improved quality of life.


Veterinary Record | 1999

Primary ciliary dyskinesia in Newfoundland dogs

Penny Watson; Michael E. Herrtage; M. A. Peacock; David R. Sargan

Primary ciliary dyskinesia was diagnosed in three Newfoundland dogs with histories of chronic rhinitis and bronchopneumonia from an early age. Thoracic radiographs of two of them showed severe, dependent bronchopneumonia and right displacement of the cardiac apex but normal positioning of other organs. Histopathological examination of sections of lung from the other dog showed severe bronchopneumonia. A semen sample from one dog had a high percentage of spermatozoa with abnormal tails and poor progressive motility. Transmission electron microscopy of nasal brushings from all three dogs showed consistent ultrastructural defects in the cilia, including an absence of outer and inner dynein arms, disorganisation of peripheral doublets, occasional supernumerary doublets and singlets, and consistently disorganised basal bodies and foot processes; sections of trachea from one dog also had disorganised basal bodies. Pedigree analysis was consistent with a monogenic autosomal recessive pattem of inheritance for the defect. One dog is still alive, one dog died aged five years two months, and one dog was euthanased aged nine months. This is the first time primary ciliary dyskinesia has been reported in Newfoundland dogs.


Journal of Veterinary Internal Medicine | 2006

Myeloma-related disorders in cats commonly present as extramedullary neoplasms in contrast to myeloma in human patients: 24 cases with clinical follow-up

Paul J. Mellor; Sean Haugland; Sue Murphy; Ken C. Smith; Andrew Holloway; Joy Archer; Roger M. Powell; Gerry A. Polton; Séverine Tasker; David McCormick; Michelle E. Tempest; Pauline E. McNeil; T. J. Scase; Chris D. Knott; Ugo Bonfanti; Elizabeth J. Villiers; David Argyle; Michael E. Herrtage; Michael J. Day

Background:Myeloma‐related disorders (MRD) are rare neoplasms of plasma cells. Published case reports describe a diversity of clinical presentations with confusing terminology and diagnostic criteria as a consequence of the assumption that MRD in cats are analogous to those in dogs or humans. Objective: The aim of the study was to describe clinical, clinicopathologic and imaging findings, response to treatment, survival and possible associations with other diseases or vaccination in a large case series. A priori hypotheses were that cats with MRD commonly present with extramedullary involvement and uncommonly have radiographic bone lesions, in contrast to human patients. Animals:Twenty‐four cats with MRD confirmed by cytology or histopathology and immunohistochemistry. Method: A multicenter retrospective study was performed. Results:Two types of clinical presentation were observed. The first group (n = 17) had neoplasia involving abdominal organs, bone marrow, or both. All developed systemic clinical signs and paraproteinemia. Five of 7 cats that received chemotherapy improved clinically or had decreased serum globulin concentration (median survival, 12.3 months; range, 8.5–22 months). The second group comprised 7 cats with skin masses, 2 of which were paraproteinemic and developed rapidly worsening systemic signs. In cats without systemic signs, excision of the skin masses appeared to be associated with prolonged survival (up to 2.4 years). Cats with MRD commonly presented with extramedullary involvement (67%), versus humans with MRD (5%) (P < .001), and uncommonly presented with radiographic bone lesions (8%) versus humans with MRD (80%) (P < .001). Conclusions: Radiographic bone lesions are uncommon in cats with MRD and extramedullary presentation is common, relative to human myeloma.

Collaboration


Dive into the Michael E. Herrtage's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

L. J. Davison

Royal Veterinary College

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Abby Caine

University of Cambridge

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joy Archer

University of Cambridge

View shared research outputs
Top Co-Authors

Avatar

Penny Watson

University of Cambridge

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge